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ABSTRACT We have introduced a substitution mutation
into the c-abl locus of murine embryonic stem cells by homol-
ogous recombination between exogenously added DNA and the
endogenous gene. Model constructs were initially generated
that consisted of a promoterless selectable neomycin resistance
marker inserted into the v-abl gene of the complete Abelson
murine leukemia virus genome, designed to be expressed either
as a fusion protein or by translational restart. Tests of these
viral genomes for transmission of v-abl and neo markers
showed more stable coexpression in a protein fusion construct.
The neo fusion was subcloned from this v-abl construct into a
promoterless c-abl fragment, and the resulting DNA was used
to transform embryonic stem cells. Direct screening of genomic
DNAs showed that a high proportion of drug-resistant clones
arose from homologous recombination into the endogenous
c-abl locus.
Abelson murine leukemia virus (Ab-MuLV) is a replication-
defective retrovirus that transforms fibroblast lines and lym-
phoid precursors in culture and induces a rapidly progressive
lymphosarcoma of B-cell origin in mice (1-3). The Ab-MuLV
genome contains a single open reading frame, formed by the
fusion ofthe 5' portion ofthe viral gag gene to exons from the
body of a mouse gene termed c-abl (4, 5). The viral gene
product, ppl60gag-abl (6, 7), is a potent tyrosine-specific
protein kinase with sequence similarity to the src family of
kinases (8, 9). The high-level kinase activity is essential for
the transforming function of the virus (10-12). A large
C-terminal region of the protein is dispensable for the trans-
formation of fibroblast lines, though alterations in this area
can affect transformation of lymphocytes and induction of
disease in animals (13, 14). This domain is also responsible for
the cytotoxic effects of the v-abl protein in certain cell types
(15).
The normal c-abl gene spans >200 kilobases (kb) (16) on
mouse chromosome 2 (17). The gene is expressed in a broad
spectrum of cell types to form at least two distinct mRNAs,
termed types I and IV, in approximately equal abundance
(18, 19). Each mRNA contains a distinctive first exon that is
spliced onto the remaining common exons that constitute the
body of the gene (20, 21). A third mRNA, truncated in the 3'
untranslated region, has been found at high levels in post-
meiotic spermatids (22, 23).
The role of the c-abl protein kinase in the physiology of the
cell, or in development of the animal, remains uncertain. The
protein, like many other tyrosine kinase enzymes, may act in
signal transduction, but because it contains no extracellular
domain it must act in concert with other membrane proteins,
and so the identification of relevant ligands is difficult. It
seems likely that a genetic approach-the analysis of muta-
tions in the c-abl gene in mice-could be helpful in under-
standing its function.
One method to generate targeted mutations in the mam-
malian genome is to select for homologous recombination
between cloned DNAs and the endogenous chromosomal
locus in embryonic stem (ES) cells and then to use these cells
to pass the mutation into the germ line (24). Work from a
number of investigators has demonstrated that DNA intro-
duced into mammalian cells by available methods integrates
by random, illegitimate recombination =100-100,000 times
more frequently than by homologous recombination (25-29).
Thus, attempts to target DNA must include some strategy for
the selection or detection of these rare homologous events.
Several procedures have been devised, including large-scale
screening (25); selection for activation of promoterless genes
(30-33); "positive-negative" selection (34); and screening by
polymerase chain reaction (33, 35-37). A number of genes
have been disrupted in mammalian cells in culture by these
methods (for review, see ref. 38).
In this paper, we report the use of homologous recombi-
nation to introduce a substitution mutation into the c-abl
locus of mouse ES cells. Detection of homologous integrants
was facilitated by the activation of a promoterless selectable
marker embedded in the gene sequences of interest. In earlier
work using similar procedures, homologous recombination
was studied between exogenous DNA and target DNA se-
quences that had been previously integrated into the mam-
malian genome (30-32) or that are counterselectable (33). We
demonstrate here that this selection mechanism is also useful
for the detection of homologous integration into nonselect-
able endogenous chromosomal loci.
EXPERIMENTAL PROCEDURES
Cloned DNAs. Plasmids p16-1, p12-27, and p12-28, linker
insertion mutants of v-abl plasmid pTabl, were as described
(11). p16-1 contains a 16-base-pair (bp) insertion including an
EcoRI site at position 4186 of v-abl. pXVX, a derivative of
pRSVneo containing multiple cloning sites in front of the
second amino acid of the neo gene and a Xho I site after the
poly(A) signal, was a generous gift of G. Gaitanaris (Colum-
bia University). Bluescript KS(-) was obtained from Strat-
agene, pIBI31 was from IBI, and pSV2neo (39) was a gift of
P. Berg (Stanford University).
Plasmid Constructions. Cloning manipulations were carried
out by standard methods (40).
v-abl-neo protein fusion constructs. Provirus pVXS, con-
taining neo sequences fused at the Xho I site of v-abl, was
constructed by inserting the 2-kb Xho I fragment of the neo
Abbreviations: ES, embryonic stem; Ab-MuLV, Abelson murine
leukemia virus; r, resistant.
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plasmid pXVX into a fragment of the Abelson provirus
produced by digestion of p16-1 with Xho I plus Sal I. Provirus
pVl6-lXR was constructed by first subcloning the 1-kb Xho
I-Sma I neo-containing fragment of pXVX into pIBI-31 and
then subcloning the 1-kb Xho I-EcoRI neo-containing frag-
ment from this intermediate into provirus p16-1 digested with
Xho I plus EcoRI.
v-abl-neo translational restart constructs. Provirus pV16-
1RR was constructed by first inserting an EcoRI site in front
of the AUG of SV2neo by site-directed mutagenesis of the
Bgl II-Sma I fragment of pSV2neo in M13mpl8 and then
subcloning the 1-kb EcoRI fragment thus generated into p16-1
at the EcoRI site. Provirus pVl6-1BR was constructed by
ligating 10-nucleotide EcoRI linkers (New England Biolabs)
onto the termini of the Bgl II-Sma I fragment of pSV2neo and
inserting that fragment into the EcoRI site of p16-i. Provi-
ruses pV12-27BR and pV12-28BR were constructed by in-
serting the same 1-kb neo-containing EcoRI fragment from
pV16-1BR into the EcoRI sites of p12-27 and p12-28, respec-
tively.
c-abl constructs. Plasmids pAbXbl and pAbXb2 were
constructed by subcloning, respectively, the 7.5-kb and the
upstream 5-kb Xba I fragments from phage Aabl2 (5) into
Bluescript KS(-). The c-abl-neo plasmid pAbXR1 was con-
structed by using the Xho I-Sal I piece containing the neo
insert from pVl6-lXR to replace the corresponding fragment
of pAbXbl.
Cells. CCE ES cells were maintained on mitomycin-treated
STO feeder layers as described (41). Cells used for electro-
porations were at passage 9-12. NIH 3T3 and STO fibro-
blasts were maintained in Dulbecco's modified Eagle medium
plus 10% calf serum (HyClone).
Introduction of DNA into ES Cells. Transformation of NIH
3T3 cells with viral DNAs was by the DEAE-dextran method
(42). CCE cells were transformed (43) in an electroporator
(Anderson Electronics, Boston) under the following condi-
tions. Cells were plated out at 3 x 106 cells per 6-cm dish, fed
on the following 2 days, and trypsinized 2 hr after the second
feeding. Trypsinized cells were washed once with phosphate-
buffered saline (PBS) and resuspended in PBS at a concen-
tration of 4 x 107 per ml. One-half milliliter of the cell
suspension was mixed with 10-20 ,Ag of plasmid pAbXR1
DNA digested with Xba I and electroporated at a variety of
voltages and capacitances to determine the best electropo-
ration conditions. Optimal conditions were obtained at 200 V
and 1000 ,uF. Cells (5 x 106) were plated onto 10-cm dishes
containing G418-resistant (G4189 feeder layers. Selections
were carried out in either of two ways. In some experiments
cells were fed fresh medium the next day and refed with
medium containing G418 at 400 ,g/ml 1.5 days after elec-
troporation. In other experiments cells were refed at 1 and 2
days after electroporation and then passed onto fresh G418r
feeder layers in medium containing G418. Cells were refed
with medium containing G418 every 2 days. Colonies were
picked into 24-well cloning trays 9-12 days after plating into
selective medium, and the G418 concentration in the medium
was lowered to 100 ,ug/ml. Cells from the 24-well trays were
plated onto two 6-cm dishes in nonselective medium. Ali-
quots of these cells were frozen and used to make high
molecular weight DNA. After screening, selected clones
were thawed, grown for two passages, and refrozen.
Probes for Southern and Northern Analyses. Probe EX was
prepared by isolating the -160-bp EcoO109-Xba I fragment
of plasmid pAbXb2 after electrophoresis in low-melting aga-
rose (Seaplaque); the DNA was labeled by extension of
hexanucleotide primers (Pharmacia) with Klenow DNA poly-
merase in the presence of [a-32P]dCTP (3000 Ci/mmol; 1 Ci
= 37 GBq; Amersham) and the three other unlabeled triphos-
phates (44). After use, blots were stripped of probe by
washing twice in 0.5 M NaOH/1.5M NaCl for 10 min at room
temperature. Stripped blots were prehybridized and rehy-
bridized with nick-translated pSV2neo probe.
RESULTS
Experimental Strategy for Disruption of the c-abl Locus. To
enrich for cells that incorporated DNA by homologous re-
combination, we designed constructs in which a promoterless
selectable marker, the neo gene, was flanked on both sides by
regions of homology to the c-abl target gene. After most
nonhomologous insertions, the neo gene would remain tran-
scriptionally silent, leaving the cell sensitive to the drug
G418. A homologous insertion event, mediated by two cross-
overs in the flanking DNA, would activate the neo gene and
render the cell G418 resistant (Fig. 1). The neo gene would be
expressed by translation of a bifunctional hybrid mRNA,
transcribed from the promoter of the endogenous c-abl gene.
In all cases we positioned the neo sequences downstream of
the protein kinase domain of the abl gene, so as to retain
kinase activity but eliminate the C-terminal one-third of the
protein.
Construction of v-abl-neo Fusions: Tests of Model Gene
Fusions. To ensure that the planned promoterless neo con-
structs would indeed confer resistance to the drug G418 when
homologous recombination occurred, we first inserted the
neo gene in v-abl-i.e., in Ab-MuLV-and tested the con-
structs for biological activity. We generated v-abl-neo con-
structs that would express the neo gene sequences in either
of two ways. In some constructs, the neo gene was designed








FIG. 1. Scheme for the replacement ofthe normal c-ablgene with
a c-abl-neo fusion by homologous recombination. A plasmid DNA
containing the neo gene embedded in c-abl sequences, but devoid of
signals for transcription and translation, is linearized by digestion
with Xba I and introduced into cells by electroporation. A double
crossover in the flanking c-abl sequences replaces the normal gene
with the fusion and activates expression of the neo gene. After
digestion ofDNA from drug-resistant clones, hybridization with the
flanking probe EX detects DNA fragments of additional sizes from
the mutant allele as well as fragments of the normal size from the
unaltered allele. A, ApaLl; X, Xba I; RI, EcoRI; RV, EcoRV.
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reinitiation (Fig. 2 A-C). In these constructs, a terminator
codon was inserted in the v-abl sequence, effectively trun-
cating the C terminus of the protein product; a complete copy
of the neo gene, including an AUG initiation codon, was
positioned immediately downstream of the terminator. The
neo sequences would then be translated to yield a separate
protein, after premature termination of translation of the
v-abl gene. In other constructs, the neo sequences were
simply inserted in frame into the coding region of the v-abl
gene, substituting the neo gene for a portion of the v-abl
sequences (Fig. 2 D and E). Such a construct would encode
a gag-abl-neo fusion protein. Since all the constructs intro-
duced alterations in the v-abl coding region downstream of
the tyrosine kinase domain, we expected them simultane-
ously to transform fibroblasts and confer G418 resistance.
The v-abl-neo constructs were introduced into NIH 3T3
fibroblasts along with DNA of the helper virus Moloney
murine leukemia virus. Virus was allowed to spread through
the culture for 3 days, and the cells were plated to assay either
for focus formation or for G418 resistance. All constructs
were able to produce foci and G418r colonies. However, only
some of the transformed foci from the translational restart
constructs were able to grow in G418, and the majority of the
colonies initially selected for drug resistance were not mor-
phologically transformed. Examination of the viral DNA
from the recipient cells revealed that the integrated provi-
ruses were generally rearranged (data not shown). In con-
trast, the constructs encoding v-abl-neo protein fusions were
able to express both markers stably. Foci of morphologically
transformed cells derived from the protein fusion viruses
grew in G418, and the majority of the colonies selected
initially in G418 appeared morphologically transformed. The
FIG. 2. Structures of v-abl-neo
constructs and nucleotide se-
quences at the abl-neo boundaries.
LTR, long terminal repeat. Top
line: structure of the wild-type Ab-
MuLV genome; the position of the
tyrosine-specific protein kinase
domain is indicated by the box.
(A-E) Structure of v-abl-neo ge-
nomes. The neo sequences are
shaded, and restriction sites flank-
ing the neo sequences are indi-
cated. The sequences at the abl-
neo boundary for each of the con-
structs are shown in the expanded
region underneath. (A-C) Transla-
tional restart constructs. The intro-
duced terminator codons are over-
lined and the AUG initiator codons
for neo expression are underlined.
(D and E) Protein fusion con-
structs. In E, the neo fragment
includes the poly(A) addition se-
quence derived from pSV2neo
(40). RI, EcoRI; X, Xba I; S, Sal I.
proviral DNA integrated in these cells was unrearranged as
judged by Southern analysis (data not shown). We therefore
concluded that the fusion virus was indeed able to express
both functions and was stably transmitted through rounds of
virus replication.
The v-abl-neo constructs were expressed at high levels
from the potent transcriptional promoter contained in the
retroviral long terminal repeat. To ensure that this high level
of transcription was not required for the expression of drug
resistance, we made an additional construct in which the
fusion was placed downstream of the relatively weak pro-
moter of the herpes simplex virus thymidine kinase gene.
Transformation of cells with this construct demonstrated that
even weak transcription was sufficient to provide drug re-
sistance (data not shown).
Homologous Recombination of c-abl-neo Fusions into the
Endogenous c-abl Gene of ES Cells. The region of v-abl
containing the abl-neo fusion was excised from the Ab-
MuLV genome of plasmid pVl6-lXR (Fig. 2D) and used to
replace the corresponding region of the c-abl gene in a cloned
7.5-kb Xba I fragment of the c-abl genomic sequence, form-
Table 1. DNA fragment sizes altered by insertion of neo




ApaLl 6.5 6.5, 7.1
Xba I 7.5 7.5, 8.1
EcoRI -32 -32, 23, 9.5
EcoRV =40 -40, 30, 10
D
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FIG. 3. Southern blot analysis of genomic DNA from individual G418r cell lines. DNA preparations from various clones were digested with
ApaLl and analyzed by Southern blotting. Lanes 1-15, clones 1-15 from experiment 3 (see Table 2); lanes 16, clone 2b1 from experiment 1.
(A) Blot was hybridized with the Abelson-specific EX probe. The bands derived from the parental c-abl allele (6.5 kb) and from the rearranged
allele (7.1 kb) are indicated by arrows. (B) The filter was stripped and rehybridized with a pSV2neo probe.
ing the plasmid pABXR1 (ref. 5; see Fig. 1). This c-abl
fragment contains c-abl exons 10, 11, and 12 but lacks any
transcriptional promoter or translational start site. When this
DNA was introduced into fibroblasts, at least 75-fold fewer
G418r colonies per gg were obtained than with the corre-
sponding viral construct.
We carried out all further experiments in the CCE ES cell
line, which has been extensively characterized and has been
shown to maintain a euploid number of chromosomes in
culture (41). Furthermore, this cell line has been shown to
provide extensive contribution to many developmental lin-
eages of chimeric animals, a crucial feature for further
studies. The plasmid containing the c-abl-neo fusion was
digested with Xba I, the DNAs were introduced into CCE ES
cells by electroporation, and the cells were plated into
medium containing G418 (see Experimental Procedures).
To detect homologous recombination events, we prepared
genomic DNAs from individual G418r clones and analyzed
the DNA by Southern blotting after digestion with ApaLI.
The filters were hybridized with a labeled probe (EX) ho-
mologous to a region of c-abl outside the introduced DNA
fragment. Integration ofthe exogenous neoDNA fragment by
homologous recombination should convert one copy of the
6.5-kb ApaLI wild-type fragment to a new 7.1-kb fragment
(Fig. 1; Table 1). Examination of DNAs from many clones
revealed the presence of this alteration in several cases (for
examples, see Fig. 3A, lanes 5,9, and 16). The submolar ratio
of rearranged to wild-type bands in some lanes results from
contamination of the ES cells by feeder cells containing only
the wild-type alleles. In four separate experiments, we iden-
tified a total of seven independent (single-copy) homologous
integration events out of 239 colonies screened, giving a
frequency of 1 in 34 G418r clones (Table 2). In these seven
cases, reprobing the blots with a probe containing neo
sequences showed hybridization only to the 7.1-kb rear-
ranged band (Fig. 3B).
The genomic DNA of five of the clones was examined
further by digesting with several other restriction enzymes,
blotting, and hybridizing with a larger v-abl probe. The
expected fragment sizes, based on the known structure of the
c-abl gene, are listed in Table 1. In four of the five clones, the
new restriction fragments were as expected for a simple
replacement of the c-abl region by the added DNA via a
double crossover (Fig. 4). In one case, however, integration
was accompanied by a rearrangement at the 3' end of the
region (Fig. 4, lanes 6). Similar rearrangements have been
observed by other investigators (refs. 31, 33; G. Gaitanaris,
M. Gottesman, D. Grieco, S. Cocozza, and E. Avvedimento,
personal communication).
We also obtained nine clones that contained alterations at
the c-abl locus that did not conform to the pattern expected
from a single substitution. Reprobing these samples with
neo-specific sequences indicated that multiple, probably tan-
dem, copies of the added DNA integrated at the c-abl locus
(Table 2). Perhaps a low level of expression ofdrug resistance
produced from the fusion construct enriched for the recovery
of clones containing multiple inserts. If we include these
clones, the proportion of the drug-resistant clones that have
undergone recombination at the c-abl locus is 1 in 15.
Although these clones contain mutations at the c-abl locus,
the complex structure of the inserted DNA dictated against
further use of these lines in genetic analyses of the c-abl
mutation.
DISCUSSION
The use of promoterless selectable markers as a means of
selecting for rare homologous recombinants has been de-
scribed by several investigators to target mutations to defined
regions of the genome of tissue culture cells (30, 31, 33). To
date, most of these mutations have been targeted to se-
quences, including simian virus 40 and polyoma viral DNA,
that were previously introduced into the genome. Our work
adds to the growing list ofgenes that have been targeted in the
mammalian genome and demonstrates that this method is a
useful form of enrichment for rare homologous recombinants
into endogenous, nonselectable loci. In the case of c-abl, we
found that 1 in 34 drug-resistant clones had undergone a
A B C
Table 2. G418r colonies carrying a mutation at the c-abl locus
Single-insert
Colonies homologous Multiple inserts
Exp. screened, no. recombinants, no. at c-abl locus, no.
1 43 1 2
2 44 0 1
3 32 2 0
4 120 4 6
Total 239 7 9
The frequency of single-copy homologous events = 1 in 34; the
frequency of all integration events at c-abl = 1 in 15.
1 2 3 4 5 6 12 3 4 5 6 1 2 3 4 5 6
FIG. 4. Southern blot analysis of genomic DNAs from five
drug-resistant cell lines. DNAs were digested with Xba I (A), EcoRI
(B), and EcoRV (C) and analyzed by Southern blotting; hybridization
was with the nick-translated pAb3sub3 probe (4). Lanes: 1, CCE
control line; 2, clone 2bl; 3, clone 34a3; 4, clone 53b6; 5, clone 55bl;
6, clone 56a8.
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homologous recombination event. Ifwe assume an =100-fold
enrichment using this technique, the ratio of unselected
homologous to nonhomologous integration events is =1 in
3400, comparable to frequencies observed at other chromo-
somal loci (refs. 30, 31, 45; L. Jeannotte, personal commu-
nication). These frequencies allow the rapid and easy detec-
tion of homologous recombinants by polymerase chain re-
action or Southern analysis. We have demonstrated in
subsequent experiments that the c-abl mutation described
here can be transmitted through the germ line of chimeric
mice obtained with the cell clones generated in this study
(46).
Promoterless selectable markers embedded in the gene
sequence of interest can be designed to be activated by that
gene's promoter in a number of different ways. The select-
able marker can be placed at or near the beginning of the
coding region of a gene and translated directly from its own
AUG codon (30, 45). Alternatively, placement of a stop
codon in the gene followed closely by the AUG of the
selectable marker can allow expression of the selectable
marker by ribosomal restart (30, 33, 47, 48). Although this
technique has been successfully applied by other investiga-
tors, we were not able to obtain active, stable constructs with
insertions in the C-terminal portion of v-abl. When we
selected for expression of drug resistance using these con-
structs, we observed rearrangements of the retroviral ge-
nome. Perhaps the location of the ribosomal restart region
near the 3' end of the mRNA or the context in which the
restart sequence was embedded did not provide a high
enough rate ofribosomal reinitiation to efficiently express the
neo gene. We have utilized a third approach, in which we
fused the abl sequences to the second codon of the neo gene,
creating a c-abl-neo fusion. This construct was based on a
similar one successfully used to target a mutation to the
thyroglobulin gene (G. Gaitanaris, M. Gottesman, D. Grieco,
S. Cocozza, and E. Avvedimento, personal communication).
We believe that the activity of this gene fusion relies on the
fact that the neo sequences begin very near to the normal N
terminus.
The activation of a selectable marker is a powerful method
for the isolation of the desired clones of cells, but it is likely
to be applicable only to transcriptionally active target genes.
Other methods, such as the positive-negative selection (34)
and the use of polymerase chain reaction for screening (33,
35-37) may permit targeting of any gene sequence for ho-
mologous recombination, whether or not it is expressed. The
use of ES cells, and the subsequent use of these cells to
generate chimeric mice, will ultimately permit the analysis of
mutations in any gene in the context of the whole organism.
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